

Fabien Praz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/198860/publications.pdf>

Version: 2024-02-01

188
papers

8,758
citations

81900

39
h-index

53230

85
g-index

199
all docs

199
docs citations

199
times ranked

5663
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2022, 43, 561-632.	2.2	2,169
2	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2021, 60, 727-800.	1.4	344
3	Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. Journal of the American College of Cardiology, 2019, 74, 2998-3008.	2.8	302
4	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. European Heart Journal, 2019, 40, 3143-3153.	2.2	297
5	Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. European Heart Journal, 2016, 37, 3503-3512.	2.2	275
6	Outcomes After Current Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2019, 12, 155-165.	2.9	246
7	Imaging Assessment of Tricuspid Regurgitation Severity. JACC: Cardiovascular Imaging, 2019, 12, 469-490.	5.3	188
8	Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet, The, 2017, 390, 773-780.	13.7	187
9	2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention, 2022, 17, e1126-e1196.	3.2	161
10	Long-Term Propensity Score-Matched Comparison of Percutaneous Closure of Patent Foramen Ovale With Medical Treatment After Paradoxical Embolism. Circulation, 2012, 125, 803-812.	1.6	160
11	Transcatheter treatment for tricuspid valve disease. EuroIntervention, 2021, 17, 791-808.	3.2	136
12	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention, 2020, 16, 371-379.	3.2	132
13	Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e002358.	3.9	107
14	The "œten commandments" for the 2021 ESC/EACTS Guidelines on valvular heart disease. European Heart Journal, 2021, 42, 4207-4208.	2.2	106
15	Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation. JACC: Cardiovascular Interventions, 2016, 9, 2308-2317.	2.9	102
16	Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 1436-1446.	2.9	99
17	Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2017, 10, 1994-2003.	2.9	96
18	Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair. Journal of the American College of Cardiology, 2022, 79, 448-461.	2.8	96

#	ARTICLE	IF	CITATIONS
19	Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (Transcatheter Heart Valve Embolization and Migration). <i>European Heart Journal</i> , 2019, 40, 3156-3165.	2.2	92
20	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020, 41, 3743-3749.	2.2	89
21	Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 577-587.	5.3	85
22	Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device. <i>EuroIntervention</i> , 2014, 10, U120-U128.	3.2	85
23	Edge-to-Edge Mitral Valve Repair With Extended Clip Arms. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1356-1365.	2.9	84
24	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	2.2	78
25	Late Results After Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism Using the Amplatzer PFO Occluder Without Intraprocedural Echocardiography. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 116-123.	2.9	77
26	Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. <i>Heart</i> , 2010, 96, 967-973.	2.9	77
27	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1353-1362.	0.6	75
28	Transatrial implantation of a transcatheter heart valve for severe mitral annular calcification. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 132-142.	0.8	69
29	Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2015, 104, 656-665.	3.3	66
30	Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1789-1799.	2.9	66
31	Impact of Right Ventricular Dysfunction on Outcomes After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 768-778.	5.3	65
32	Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1324-1334.	2.9	63
33	Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2173-2182.	2.9	60
34	Assessment of right ventricular systolic function: Comparison between cardiac magnetic resonance derived ejection fraction and pulsed-wave tissue Doppler imaging of the tricuspid annulus. <i>International Journal of Cardiology</i> , 2011, 151, 58-62.	1.7	56
35	Rates and predictors of hospital readmission after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 2211-2217.	2.2	54
36	Expanding Indications of Transcatheter Heart Valve Interventions. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1777-1796.	2.9	53

#	ARTICLE	IF	CITATIONS
37	Effect of B-type Natriuretic Peptides on Long-Term Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2015, 116, 1560-1565.	1.6	47
38	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021, 17, e898-e909.	3.2	45
39	Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1438-1447.	2.9	44
40	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1999-2009.	2.9	42
41	Impact of Proportionality of Secondary Mitral Regurgitation on Outcome After Transcatheter Mitral Valve Repair. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 715-725.	5.3	42
42	Hemodynamic Relevance of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva-In Search of the Evidence. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 591326.	2.4	42
43	Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2022, 18, 33-42.	3.2	42
44	Postprocedural Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	41
45	Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. <i>EuroIntervention</i> , 2021, 17, e343-e352.	3.2	41
46	Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 704-717.	2.9	39
47	Impact of Residual Mitral Regurgitation on Survival After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1243-1253.	2.9	39
48	Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1374-1383.	2.9	38
49	Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006132.	3.9	38
50	Mitral regurgitation in heart failure: time for a rethink. <i>European Heart Journal</i> , 2019, 40, 2189-2193.	2.2	38
51	Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1503-1514.	2.9	38
52	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. <i>American Journal of Cardiology</i> , 2016, 118, 1888-1896.	1.6	37
53	Comparison between Three-Dimensional Echocardiography and Computed Tomography for Comprehensive Tricuspid Annulus and Valve Assessment in Severe Tricuspid Regurgitation: Implications for Tricuspid Regurgitation Grading and Transcatheter Therapies. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 1190-1202.e3.	2.8	37
54	Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. <i>Open Heart</i> , 2018, 5, e000695.	2.3	36

#	ARTICLE	IF	CITATIONS
55	Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 398-404.	1.2	36
56	Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 820-830.	2.9	36
57	Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. <i>European Heart Journal</i> , 2022, 43, 641-650.	2.2	36
58	Transcatheter aortic valve implantation with the NVT Allegra transcatheter heart valve system: first-in-human experience with a novel self-expanding transcatheter heart valve. <i>EuroIntervention</i> , 2016, 12, 71-77.	3.2	35
59	New-onset arrhythmias following transcatheter aortic valve implantation: a systematic review and meta-analysis. <i>Heart</i> , 2018, 104, 1208-1215.	2.9	34
60	Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2408-2421.	2.8	34
61	Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. <i>European Journal of Heart Failure</i> , 2022, 24, 899-907.	7.1	33
62	Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1843-1851.	5.3	33
63	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 554-564.	2.9	32
64	Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. <i>European Journal of Heart Failure</i> , 2022, 24, 887-898.	7.1	32
65	Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients. <i>Swiss Medical Weekly</i> , 2008, 138, 567-72.	1.6	30
66	The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2017, 184, 71-80.	2.7	29
67	Transcatheter aortic valve replacement in patients with concomitant mitral stenosis. <i>European Heart Journal</i> , 2019, 40, 1342-1351.	2.2	29
68	Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement?. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 522-532.	1.2	28
69	Optimal Fluoroscopic Projections of Coronary Ostia and Bifurcations Defined by Computed Tomographic Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2560-2570.	2.9	28
70	Patent Foramen Ovale May Be Causal for the First Stroke but Unrelated to Subsequent Ischemic Events. <i>Stroke</i> , 2011, 42, 2891-2895.	2.0	26
71	Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality. <i>Heart</i> , 2015, 101, 30-36.	2.9	26
72	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009685.	3.9	26

#	ARTICLE	IF	CITATIONS
73	Impact of Mitral Regurgitation on Clinical Outcomes of Patients With Low-Ejection Fraction, Low-Gradient Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001895.	3.9	25
74	Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E38-E43.	1.7	25
75	Fluoroscopic Anatomy of Right-Sided Heart Structures for Transcatheter Interventions. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1614-1625.	2.9	25
76	Sex-Related Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 819-827.	2.9	24
77	Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2022, 79, 513-526.	2.8	24
78	Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2015, 4, e002135.	3.7	23
79	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. <i>International Journal of Cardiology</i> , 2017, 243, 150-155.	1.7	23
80	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1665-1675.	2.9	23
81	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.	3.7	23
82	Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 124-129.	1.7	22
83	Nuss procedure for pectus excavatum in adults: long-term results in a prospective observational study. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 934-939.	1.4	22
84	Refined staging classification of cardiac damage associated with aortic stenosis and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 532-541.	4.0	22
85	Multicenter Experience With the Transcatheter Leaflet Repair System for Symptomatic Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1352-1363.	2.9	22
86	Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: CardioOncology</i> , 2019, 1, 145-155.	4.0	20
87	Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 356-365.	1.3	20
88	Imaging and Patient Selection for Transcatheter Tricuspid Valve Interventions. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 60.	2.4	20
89	Potential Candidates for Transcatheter Tricuspid Valve Intervention After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2246-2256.	2.9	20
90	Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 709-714.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2017, 120, 2025-2030.	1.6	18
92	Valvular and Nonvalvular Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2124-2133.	2.9	18
93	Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011302.	3.9	17
94	The PASCAL Device—Early Experience with a Leaflet Approximation Device: What Are the Benefits/Limitations Compared with the MitraClip?. <i>Current Cardiology Reports</i> , 2020, 22, 74.	2.9	16
95	Amplatzer patent foramen ovale occluder: safety and efficacy. <i>Expert Review of Medical Devices</i> , 2019, 16, 173-182.	2.8	15
96	Surgical versus transcatheter repair for secondary mitral regurgitation: A propensity score–matched cohorts comparison. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 2037-2046.e4.	0.8	15
97	Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale. <i>EuroIntervention</i> , 2017, 13, 858-866.	3.2	15
98	Transcarotid aortic valve-in-valve implantation for degenerated stentless aortic root conduits with severe regurgitation: a case series. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 20, 694-700.	1.1	14
99	Transcatheter Tricuspid Valve-in-Valve Intervention for Degenerative Bioprosthetic Tricuspid Valve Disease. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 491-504.	2.8	14
100	Percutaneous Mitral Edge-to-Edge Repair: State of the Art and a Glimpse to the Future. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 122.	2.4	14
101	Validation of the 2019 Expert Consensus Algorithm for the Management of Conduction Disturbances After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 981-991.	2.9	14
102	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006741.	3.9	13
103	Imaging in patients with severe mitral annular calcification: insights from a multicentre experience using transatrial balloon-expandable valve replacement. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1395-1406.	1.2	13
104	Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis. <i>International Journal of Cardiology</i> , 2019, 290, 45-51.	1.7	13
105	Anatomical and Technical Predictors of Three-Dimensional Mitral Valve Area Reduction After Transcatheter Edge-To-Edge Repair. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 96-104.	2.8	13
106	Cerebral protection devices for transcatheter aortic valve implantation: is better the enemy of good?. <i>EuroIntervention</i> , 2013, 9, S124-S128.	3.2	13
107	Latest evidence on transcatheter aortic valve implantation vs. surgical aortic valve replacement for the treatment of aortic stenosis in high and intermediate-risk patients. <i>Current Opinion in Cardiology</i> , 2017, 32, 117-122.	1.8	12
108	External validity of the all-comers design: insights from the BIOSCIENCE trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 744-754.	3.3	11

#	ARTICLE	IF	CITATIONS
109	A New Age for Transcatheter Mitral Valve Repair. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2415-2417.	2.9	11
110	Permanent pacemaker implantation late after transcatheter aortic valve implantation. <i>Heart Rhythm</i> , 2021, 18, 2033-2039.	0.7	11
111	Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2018, 250, 73-79.	1.7	11
112	Validation of the VARC-3 Technical Success Definition in Patients Undergoing TAVR. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 353-364.	2.9	11
113	Clinical relevance of coronary angiography at the time of percutaneous closure of a patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 641-645.	1.7	10
114	Prognostic impact of invasive haemodynamic measurements in combination with clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2017, 12, e2186-e2193.	3.2	10
115	Safety, feasibility, and long-term results of percutaneous closure of atrial septal defects using the Amplatzer septal occluder without periprocedural echocardiography. <i>Journal of Invasive Cardiology</i> , 2015, 27, 157-62.	0.4	10
116	Mitral and Tricuspid Transcatheter Interventions Current Indications and Future Directions. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 61.	2.4	8
117	Impact of effective regurgitant orifice area on outcome of secondary mitral regurgitation transcatheter repair. <i>Clinical Research in Cardiology</i> , 2021, 110, 732-739.	3.3	8
118	Staging cardiac damage associated with aortic stenosis in patients undergoing transcatheter aortic valve implantation. <i>IJC Heart and Vasculature</i> , 2021, 33, 100768.	1.1	8
119	Deep learning-based prediction of early cerebrovascular events after transcatheter aortic valve replacement. <i>Scientific Reports</i> , 2021, 11, 18754.	3.3	8
120	Assessment of low-flow, low-gradient, severe aortic stenosis: an invasive evaluation is required for decision making. <i>EuroIntervention</i> , 2014, 10, U61-U68.	3.2	8
121	A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneous patent foramen ovale closure in recurrent clinical) <i>TJ ETQq1 1 03284314 rgBT /Ove</i>		
122	Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>American Heart Journal</i> , 2022, 244, 94-106.	2.7	8
123	Imaging-Based, Patient-Specific Three-Dimensional Printing to Plan, Train, and Guide Cardiovascular Interventions: A Systematic Review and Meta-Analysis. <i>Heart Lung and Circulation</i> , 2022, 31, 1203-1218.	0.4	8
124	Heart valve sizing and clinical outcomes in patients undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E768-E779.	1.7	7
125	Management and Outcome of Failed Percutaneous Edge-to-Edge Mitral Valve Plasty. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 411-422.	2.9	7
126	Transcatheter Aortic Valve Replacement via the Transcarotid Access. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007459.	3.9	6

#	ARTICLE	IF	CITATIONS
127	PASCAL. JACC: Cardiovascular Interventions, 2019, 12, 1379-1381.	2.9	6
128	Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction. Journal of Clinical Medicine, 2021, 10, 1819.	2.4	6
129	Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation. BMC Cardiovascular Disorders, 2022, 22, 178.	1.7	6
130	Case report of simultaneous transcatheter mitral valve-in-valve implantation and percutaneous closure of two paravalvular leaks. European Heart Journal - Case Reports, 2019, 3, ytz123.	0.6	5
131	Plaque erosion causing ST-elevation myocardial infarction after consumption of cannabis and N2O in a 27-year old man: a case report. BMC Cardiovascular Disorders, 2021, 21, 147.	1.7	5
132	Transcatheter aortic valve implantation today and tomorrow. Swiss Medical Weekly, 2016, 146, w14299.	1.6	5
133	Optimal fluoroscopic viewing angles of right-sided heart structures in patients with tricuspid regurgitation based on multislice computed tomography. EuroIntervention, 2019, 15, .	3.2	5
134	Acute coronary syndromes in young patients: Phenotypes, causes and clinical outcomes following percutaneous coronary interventions.. International Journal of Cardiology, 2022, 350, 1-8.	1.7	5
135	Effect of Right Ventricular Function and Tricuspid Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	4
136	Surgical Transatrial Implantation of Transcatheter Heart Valves in Severe Mitral Annular Calcification. Interventional Cardiology Clinics, 2019, 8, 313-319.	0.4	4
137	Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e006612.	3.9	4
138	Prosthesisâ€“Patient Mismatch Based on Energy Loss Index After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2584-2586.	2.9	4
139	Functional assessment of myocardial ischaemia by intracoronary ECG. Open Heart, 2021, 8, e001447.	2.3	4
140	True-severe stenosis in paradoxical low-flow low-gradient aortic stenosis: outcomes after transcatheter aortic valve replacement. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 366-377.	4.0	4
141	Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves. JACC: Cardiovascular Interventions, 2021, 14, 873-878.	2.9	4
142	Hemolysis After Transcatheter Mitral Valve Implantation Resolved by Valve Retensioning. JACC: Case Reports, 2021, 3, 864-870.	0.6	4
143	Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. Canadian Journal of Cardiology, 2021, 37, 1094-1102.	1.7	4
144	Effect of resting heart rate on two-year clinical outcomes of high-risk patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 12, 490-498.	3.2	4

#	ARTICLE	IF	CITATIONS
145	Retrograde Retrieval of a Novel Large Mitral Clip After Embolization Into the Left Ventricle. <i>JACC: Case Reports</i> , 2021, 3, 1561-1568.	0.6	4
146	Clinical outcomes following transcatheter aortic valve implantation in patients with porcelain aorta. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 215-221.	1.3	4
147	Electrosurgical Laceration and Stabilization of MitraClip Followed by Valve Implantation for Iatrogenic Mitral Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 110-112.	2.9	4
148	Risk and Timing of Noncardiac Surgery After Transcatheter Aortic Valve Implantation. <i>JAMA Network Open</i> , 2022, 5, e2220689.	5.9	4
149	Response To Letter Regarding Article, "Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification". <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e003064.	3.9	3
150	Deferred versus Expedited Aortic Valve Replacement in Patients with Symptomatic Severe Aortic Stenosis During the SARS-CoV-2 Pandemic (AS DEFER): A Research Letter. <i>Global Heart</i> , 2021, 16, 32.	2.3	3
151	Interventional treatment of mitral valve regurgitation: an alternative to surgery?. <i>Swiss Medical Weekly</i> , 2019, 149, w20023.	1.6	3
152	Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis. <i>Heart</i> , 2022, 108, 1225-1233.	2.9	3
153	Pitfalls in TAMVI: experience with the repositionable Lotus® Valve System. <i>Journal of Cardiothoracic Surgery</i> , 2017, 12, 47.	1.1	2
154	Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 140, 95-102.	1.6	2
155	Systemic Corticosteroid Exposure and Atrioventricular Conductance Delays After Transcatheter Aortic Valve Implantation. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 1-6.	0.8	2
156	Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1354-1364.	1.2	2
157	Bilateral, reversible coronary obstruction during aortic valve-in-valve implantation of a repositionable valve system. <i>EuroIntervention</i> , 2016, 12, 1195-1195.	3.2	2
158	OUP accepted manuscript. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, , .	1.4	2
159	Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021, 10, e023129.	3.7	2
160	Impact of First-Phase Ejection Fraction on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Cardiovascular Revascularization Medicine</i> , 2022, 42, 55-61.	0.8	2
161	Assessment of New Onset Arrhythmias After Transcatheter Aortic Valve Implantation Using an Implantable Cardiac Monitor. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	2
162	Percutaneous Tricuspid Valve Repair. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 220.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Long-term follow-up after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism in elderly patients (≥70 years). <i>European Geriatric Medicine</i> , 2012, 3, 23-27.	2.8	1
164	Short-term catheter based treatment of aortic regurgitation by Edwards' Sapien 3 valve-in-valve implantation because of a poorly placed Medtronic CoreValve. <i>International Journal of Cardiology</i> , 2016, 207, 120-121.	1.7	1
165	Two-year outcomes of the MITRA-ER trial: towards an integrated approach in the evaluation of patients with secondary mitral regurgitation. <i>European Journal of Heart Failure</i> , 2019, 21, 1628-1631.	7.1	1
166	Reply. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2446-2447.	2.9	1
167	Transcatheter tricuspid valve treatment: does annular reduction make a difference?. <i>EuroIntervention</i> , 2021, 16, e1213-e1214.	3.2	1
168	The role of transcatheter mitral valve leaflet approximation for the treatment of secondary mitral regurgitation: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2021, 18, 261-272.	2.8	1
169	Integrative echocardiographic assessment of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1404-1412.	1.7	1
170	Transcatheter Edge-to-Edge Repair Gives Years to Life and Life to Years to Elderly Patients With Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, , .	2.9	1
171	Cardiovascular outcomes in patients with left atrial enlargement undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	1.7	1
172	Caval Valve Implantation for Advanced Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1378-1381.	2.9	1
173	Emboic protection for tricuspid valve-in-valve intervention. <i>European Heart Journal</i> , 2018, 39, 1748-1748.	2.2	0
174	Impact of Resting Heart Rate at 30 Days Following Transcatheter or Surgical Aortic Valve Replacement and Cardiovascular Outcomes: Insights from The PARTNER 2 Trial. <i>Structural Heart</i> , 2018, 2, 441-447.	0.6	0
175	TCT-753 Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prosthesis. <i>Journal of the American College of Cardiology</i> , 2019, 74, B739.	2.8	0
176	Valvular Resistance and Bleeding Events Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Structural Heart</i> , 2019, 3, 220-228.	0.6	0
177	Percutaneous patent foramen ovale closure during live case demonstrations. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 982-988.	1.7	0
178	An unusual cause of recurrent mitral regurgitation after percutaneous mitral valve repair. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E393-E394.	1.7	0
179	Adding a Clasp to the Toolbox for Transcatheter Mitral Valve Repair. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2358-2360.	2.9	0
180	Editorial: Percutaneous Mitral Valve Interventions (Repair): Current Indications and Future Perspectives. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 581109.	2.4	0

#	ARTICLE	IF	CITATIONS
181	Synergistic Effect of 2 Transcatheter Tricuspid Valve Treatment Modalities. JACC: Cardiovascular Interventions, 2021, 14, e5-e7.	2.9	0
182	Learning From Failure at the CUTTING-EDGE of Transcatheter Mitral Valve Therapies. JACC: Cardiovascular Interventions, 2021, 14, 2022-2026.	2.9	0
183	Multimodality Imaging for Evaluation of Bicaval Valved Stent Implantation in Severe Tricuspid Regurgitation. JACC: Case Reports, 2021, 3, 1512-1518.	0.6	0
184	A case of myocardial infarction with conduction abnormalities. Cardiovascular Medicine(Switzerland), 0, , .	0.0	0
185	Transcatheter treatment of multivalvular heart disease. EuroIntervention, 2020, 16, 858-859.	3.2	0
186	Accidental closure of the left upper pulmonary vein with an Amplatzer atrial septal defect occluder. Journal of Invasive Cardiology, 2012, 24, E219-21.	0.4	0
187	Impact of right ventricular dysfunction after mitraclip treatment as a bridge to heart transplantation: insight from the mitrbridge strategy. European Heart Journal Supplements, 2021, 23, .	0.1	0
188	Reply: The time has come to use attitudinally appropriate terminology when describing cardiac anatomy. EuroIntervention, 2022, 17, 1539-1540.	3.2	0